Navigation Links
New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis
Date:11/8/2007

RD and OPTION studies will be part of the application to Regulatory Authorities that we intend to submit by the end of the year."

About TOWARD Study

Patients were randomized to receive either Actemra intravenously (8mg/kg) every four weeks plus DMARDs weekly or placebo infusions plus DMARDs weekly. The multicentre study treated 1,216 patients at 130 trial sites in 18 countries, including the U.S. At 24 weeks significantly more patients achieved a 20%, 50% and 70% (ACR20, ACR50 and ACR70) reduction of symptoms with Actemra plus DMARDs compared to the control group. The ACR20, ACR50 and ACR70 was achieved in 61%, 38% and 21%, respectively, of Actemra plus DMARDs patients versus 25%, 9% and 3%, respectively, in the placebo plus DMARDs arm. Disease remission was demonstrated in 30% of Actemra patients (DAS28 <2.6) compared with 3% of patients treated with only DMARDs.

About OPTION Study

In the OPTION trial, 623 patients were randomized to receive Actemra intravenously (either 4mg/kg or 8mg/kg) every four weeks plus methotrexate weekly or placebo infusions plus methotrexate weekly. The study was conducted in 73 trial sites in 17 countries, outside the United States. At 24 weeks significantly more patients achieved a 20%, 50% and 70% (ACR20, ACR50 and ACR70) reduction of symptoms with Actemra plus methotrexate compared to the control arm. Fifty nine per cent, 44% and 22%, respectively, of patients treated with Actemra (8mg/kg) plus methotrexate achieved ACR20, ACR50 and ACR70 compared with 27%, 11% and 2%, respectively, in the control group. Disease remission was demonstrated in 28% of Actemra patients (DAS28 <2.6) compared with 1% of patients treated with methotrexate alone.

Other parameters measured in both studies included levels of C-reactive protein (CRP), a marker of inflammation, fatigue and haemoglobin. Patients on Actemra showed a rapid normalisation of the CPR levels within two weeks and a rapid improvem
'/>"/>

Contact: Nicole Moores
nicole_moores@uk.cohnwolfe.com
44-020-733-15337
Cohn & Wolfe, London
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Clones on task serve greater good, evolutionary study shows
3. Study shows link between alcohol consumption and hiv disease progression
4. Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
5. New study shows greenback cutthroat trout involved in recovery effort misidentified
6. DNA analysis shows true dispersal of protozoa
7. New genetic research into nicotine addiction shows promise for personalized treatment
8. International team shows mercury concentrations in fish respond quickly to increased deposition
9. New study shows fish respond quickly to changes in mercury deposition
10. Amazon forest shows unexpected resiliency during drought
11. New study shows fish respond quickly to changes in mercury deposition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... reserves of methane gas seeping from the melting Arctic ice ... knew: As the permafrost thaws, there is a release of ... The trick was figuring out how much, said Chanton, the ... The four-member team whose findings were published in ...
... rooms finds television remotes to be among the most ... carry the potential to cross-contaminate rooms. Researchers from ... the 2012 General Meeting of the American Society for ... guests with a safe and secure environment. Currently, ...
... In Israel,s Negev Desert, a plant called sweet mignonette or ... the spiny mouse spit out the plant,s seeds when eating ... into a seed spreader that helps the plant reproduce, says ... fascinating that these little mice are doing analytical chemistry, assaying ...
Cached Biology News:Study: Seeking Arctic methane has serious implications for Florida coastline 2The most contaminated surfaces in hotel rooms 2Ptooey! 2Ptooey! 3Ptooey! 4
(Date:12/24/2014)... December 23, 2014 ... is designed to introduce cutting edge communication ... and partners of platform upgrades. This webinar ... empowering users in their quest to leverage ... , According to SoundConnect’s Marketing Manager, Seanna ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and ... free download , digs deep into this vibrant market, ... sector today. One area where Algeria ... a homegrown pharmaceutical manufacturing base, even if the government,s ambitious ... off. A cursory comparison with neighboring Morocco ...
Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... SOUTH SAN FRANCISCO, Calif., Jan. 12 Sunesis Pharmaceuticals, ... clinical update on voreloxin, its novel investigational drug candidate ... myeloid leukemia (AML) and ovarian cancer. The clinical ... Annual JP Morgan Healthcare Conference in San Francisco. "2008 ...
... Calif., Jan. 12 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical programs, Unit Dose Budesonide (UDB) for children,with ... For UDB, all,patients have completed the 12 week ... for MAP0004, the company currently expects to complete,enrollment in ...
... Calif., Jan. 12 Anacor Pharmaceuticals today,announced that it ... million from its collaboration partner, GlaxoSmithKline. Anacor may,receive ... to clinical development and commercial sales. , ... we have made as a result of,the alliance we ...
Cached Biology Technology:Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 2Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 3Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 4Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 5Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 6MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate 2
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
... Physical Form: buffered aqueous solution. ... terminal galactose from complex carbohydrates and glycoproteins. ... galactose under conditions where the pH must ... live cells. Unit Definition: ...
... is specific for human cardiac troponin subunit T, ... signals responsible for contraction of cardiac muscle. It ... in human cells. It also cross-reacts with human ... Antigen: Highly purified human cardiac troponin ...
cystatin A (N-18)...
Biology Products: